United Therapeutics Corporation (UTHR)

$367.36

+3.03

(+0.83%)▲

Market is closed - opens 8 PM, 22 Nov 2024

Performance

  • $361.79
    $370.34
    $367.36
    downward going graph

    1.52%

    Downside

    Day's Volatility :2.31%

    Upside

    0.8%

    downward going graph
  • $208.62
    $417.82
    $367.36
    downward going graph

    43.21%

    Downside

    52 Weeks Volatility :50.07%

    Upside

    12.08%

    downward going graph

Returns

PeriodUnited Therapeutics CorporationSector (Health Care)Index (Russel 2000)
3 Months
3.62%
-7.6%
0.0%
6 Months
32.39%
-2.3%
0.0%
1 Year
58.11%
10.1%
0.0%
3 Years
83.16%
7.5%
-24.5%

Highlights

Market Capitalization
16.3B
Book Value
$136.74
Earnings Per Share (EPS)
22.76
PE Ratio
16.01
PEG Ratio
1.56
Wall Street Target Price
382.294
Profit Margin
40.31%
Operating Margin TTM
54.51%
Return On Assets TTM
11.89%
Return On Equity TTM
18.81%
Revenue TTM
2.8B
Revenue Per Share TTM
60.25
Quarterly Revenue Growth YOY
22.900000000000002%
Gross Profit TTM
1.8B
EBITDA
1.4B
Diluted Eps TTM
22.76
Quarterly Earnings Growth YOY
0.19
EPS Estimate Current Year
24.51
EPS Estimate Next Year
27.82
EPS Estimate Current Quarter
6.41
EPS Estimate Next Quarter
6.57

Analyst Recommendation

Buy
    81%Buy
    13%Hold
    4%Sell
Based on 22 Wall street analysts offering stock ratings for United Therapeutics Corporation(by analysts ranked 0 to 5 stars)
Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
18
17
Hold
3
3
2
Sell
1
1
2

Analyst Forecast

What analysts predicted

Upside of 4.07%

Current $367.36
Target $382.29

Company Financials

FY18Y/Y Change
Revenue
1.6B
↓ 5.65%
Net Income
589.2M
↑ 40.99%
Net Profit Margin
36.2%
↑ 11.98%
FY19Y/Y Change
Revenue
1.4B
↓ 11.0%
Net Income
-104.5M
↓ 117.74%
Net Profit Margin
-7.21%
↓ 43.41%
FY20Y/Y Change
Revenue
1.5B
↑ 2.38%
Net Income
514.8M
↓ 592.63%
Net Profit Margin
34.71%
↑ 41.92%
FY21Y/Y Change
Revenue
1.7B
↑ 13.63%
Net Income
475.8M
↓ 7.58%
Net Profit Margin
28.23%
↓ 6.48%
FY22Y/Y Change
Revenue
1.9B
↑ 14.88%
Net Income
727.3M
↑ 52.86%
Net Profit Margin
37.56%
↑ 9.33%
FY23Y/Y Change
Revenue
2.3B
↑ 20.2%
Net Income
984.8M
↑ 35.4%
Net Profit Margin
42.31%
↑ 4.75%
Q2 FY23Q/Q Change
Revenue
596.5M
↑ 17.68%
Net Income
259.2M
↑ 7.6%
Net Profit Margin
43.45%
↓ 4.07%
Q3 FY23Q/Q Change
Revenue
609.4M
↑ 2.16%
Net Income
267.6M
↑ 3.24%
Net Profit Margin
43.91%
↑ 0.46%
Q4 FY23Q/Q Change
Revenue
614.7M
↑ 0.87%
Net Income
217.1M
↓ 18.87%
Net Profit Margin
35.32%
↓ 8.59%
Q1 FY24Q/Q Change
Revenue
677.7M
↑ 10.25%
Net Income
306.6M
↑ 41.23%
Net Profit Margin
45.24%
↑ 9.92%
Q2 FY24Q/Q Change
Revenue
714.9M
↑ 5.49%
Net Income
278.1M
↓ 9.3%
Net Profit Margin
38.9%
↓ 6.34%
Q3 FY24Q/Q Change
Revenue
748.9M
↑ 4.76%
Net Income
309.1M
↑ 11.15%
Net Profit Margin
41.27%
↑ 2.37%
FY18Y/Y Change
Total Assets
3.4B
↑ 18.11%
Total Liabilities
612.4M
↓ 21.24%
FY19Y/Y Change
Total Assets
3.9B
↑ 15.07%
Total Liabilities
1.1B
↑ 85.01%
FY20Y/Y Change
Total Assets
4.6B
↑ 17.93%
Total Liabilities
1.2B
↑ 7.66%
FY21Y/Y Change
Total Assets
5.2B
↑ 12.01%
Total Liabilities
1.2B
↓ 0.79%
FY22Y/Y Change
Total Assets
6.0B
↑ 16.94%
Total Liabilities
1.2B
↑ 3.11%
FY23Y/Y Change
Total Assets
7.2B
↑ 18.57%
Total Liabilities
1.2B
↓ 5.26%
Q2 FY23Q/Q Change
Total Assets
6.7B
↑ 5.28%
Total Liabilities
1.3B
↑ 3.88%
Q3 FY23Q/Q Change
Total Assets
7.0B
↑ 5.12%
Total Liabilities
1.3B
↑ 3.24%
Q4 FY23Q/Q Change
Total Assets
7.2B
↑ 2.04%
Total Liabilities
1.2B
↓ 9.86%
Q1 FY24Q/Q Change
Total Assets
6.5B
↓ 9.37%
Total Liabilities
1.2B
↓ 2.12%
Q2 FY24Q/Q Change
Total Assets
6.7B
↑ 3.51%
Total Liabilities
1.0B
↓ 11.33%
Q3 FY24Q/Q Change
Total Assets
7.1B
↑ 5.95%
Total Liabilities
1.0B
↓ 0.37%
FY18Y/Y Change
Operating Cash Flow
778.4M
↑ 64.15%
Investing Cash Flow
-820.6M
↓ 1.8%
Financing Cash Flow
6.3M
↓ 85.45%
FY19Y/Y Change
Operating Cash Flow
-206.6M
↓ 126.54%
Investing Cash Flow
-335.4M
↓ 59.13%
Financing Cash Flow
611.2M
↑ 9601.59%
FY20Y/Y Change
Operating Cash Flow
755.7M
↓ 465.78%
Investing Cash Flow
-738.5M
↑ 120.18%
Financing Cash Flow
-16.9M
↓ 102.77%
FY21Y/Y Change
Operating Cash Flow
598.2M
↓ 20.84%
Investing Cash Flow
-486.9M
↓ 34.07%
Financing Cash Flow
44.8M
↓ 365.09%
FY22Y/Y Change
Operating Cash Flow
802.5M
↑ 34.15%
Investing Cash Flow
-811.5M
↑ 66.67%
Financing Cash Flow
75.4M
↑ 68.3%
Q2 FY23Q/Q Change
Operating Cash Flow
106.3M
↓ 71.64%
Investing Cash Flow
-227.2M
↑ 2.76%
Financing Cash Flow
24.7M
↓ 49.18%

Technicals Summary

Sell

Neutral

Buy

United Therapeutics Corporation is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
United Therapeutics Corporation
United Therapeutics Corporation
-1.69%
32.39%
58.11%
83.16%
104.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-23.25%
-25.21%
-6.95%
15.49%
111.91%
Biontech Se
Biontech Se
-8.46%
10.94%
5.13%
-68.25%
419.0%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-14.8%
66.28%
52.0%
33.04%
123.73%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.62%
2.09%
27.19%
148.61%
109.39%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
United Therapeutics Corporation
United Therapeutics Corporation
15.84
16.01
1.56
24.51
0.19
0.12
NA
136.74
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.73
18.73
1.13
44.87
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.04
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.22
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
United Therapeutics Corporation
United Therapeutics Corporation
Buy
$16.3B
104.89%
15.84
40.31%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$83.2B
111.91%
18.73
33.61%
Biontech Se
Biontech Se
Buy
$23.9B
419.0%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
123.73%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.3B
109.39%
32.84
-4.51%

Insights on United Therapeutics Corporation

  • Increasing Revenue

    Revenue is up for the last 8 quarters, 491.5M → 748.9M (in $), with an average increase of 5.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 278.1M → 309.1M (in $), with an average increase of 10.0% per quarter

Institutional Holdings

  • BlackRock Inc

    12.25%

  • Vanguard Group Inc

    9.88%

  • Wellington Management Company LLP

    7.36%

  • venBio Select Advisor LLC

    6.40%

  • State Street Corp

    5.14%

  • Renaissance Technologies Corp

    4.83%

Company Information

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians

Organization
United Therapeutics Corporation
Employees
1168
CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Industry
Health Technology

FAQs